Randomized Trial on 14 versus 7 days of Esomeprazole, Moxifloxacin, and Amoxicillin for Second-line or Rescue Treatment of Helicobacter pylori Infection

Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design

(2010) J. M. Liou et al.   GUT

One-Week Once-Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin

(2010) Stephan Miehlke et al.   HELICOBACTER

Should quinolones come first in Helicobacter pylori therapy?

(2010) Marco Berning et al.   Therapeutic Advances in Gastroenterology

Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment

(2009) F. Sacco et al.   DIGESTIVE AND LIVER DISEASE

Prevalence of Primary Fluoroquinolone Resistance Among Clinical Isolates ofHelicobacter pyloriat a University Hospital in Southern Taiwan

(2009) Kuei-Hsiang Hung et al.   HELICOBACTER

Moxifloxacin-Containing Triple Therapy as Second-Line Treatment for Helicobacter pylori Infection: Effect of Treatment Duration and Antibiotic Resistance on the Eradication Rate

(2009) Hyuk Yoon et al.   HELICOBACTER

Levofloxacin, Amoxicillin, and Omeprazole as First-line Triple Therapy for Helicobacter pylori Eradication

(2009) Javier P. Gisbert et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Resistance to metronidazole, clarithromycin and levofloxacin ofHelicobacter pyloribefore and after clarithromycin-based therapy in Taiwan

(2009) Wei-Lun Chang et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK

(2009) S. A. Chisholm et al.   JOURNAL OF MEDICAL MICROBIOLOGY

Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial

(2009) Josip Bago et al.   WIENER KLINISCHE WOCHENSCHRIFT

S3-Guideline ”Helicobacter pylori and gastroduodenal ulcer disease” of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-Registration-no. 021 / 001

(2009) W. Fischbach et al.   ZEITSCHRIFT FUR GASTROENTEROLOGIE

Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication

(2008) S. Di Caro et al.   DIGESTIVE AND LIVER DISEASE

Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study of 300 Patients

(2007) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY